ECS Botanics Holdings (ASX:ECS) is set to supply its Avani THC10 soft gel capsules to support an upcoming investigator-led clinical trial by the Center for Sleep Science at the University of Western Australia, to assess the therapeutic potential of medicinal cannabis in patients with clinically-significant obstructive sleep apnea, according to a Monday Australian bourse filing.
It will examine the impact of 10 milligrams of tetrahydrocannabinol on obstructive sleep apnea severity and contributing physiological mechanisms, along with psychomotor and cognitive outcomes.
The trial targets the enrollment of 24 participants and is expected to open within the year. Recruitment is expected to begin in July.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.